NCT05888233CompletedPhase 2
Allopurinol Improves Heart Function in African Americans With Resistant Hypertension
Allopurinol Improves Diastolic Function in African Americans With Resistant Hypertension
Source: ClinicalTrials.gov · Last updated 4 Sept 2026
Brief summary (registry, in English)
African American adults in the United States have the highest prevalence rate of high blood pressure (hypertension) and heart failure in the world. African Americans with treatment resistant hypertension have higher levels of the enzyme - xanthine oxidase compared to Caucasians. This trial will test if administration of the xanthine oxidase inhibitor - Allopurinol (commonly used in the treatment of gout), given over a period of 8 weeks, will improve heart function, exercise ability and quality of life in African American Veterans with resistant hypertension.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 2 May 2023
- Start date
- 30 Sept 2024
- Primary completion date
- 30 Apr 2026
- Lead sponsor
- VA Office of Research and Development
- Diseases
- Heart failure, High blood pressure
- NCT number
- NCT05888233
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 40
- From 30 Sept 2024 to the primary completion date, 30 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Chronic steroid therapy
Other illness
- History of heart failure
- Known coronary artery disease
- Known causes of secondary hypertension
- Cardiac implantable electronic device (permanent pacemaker and/or intracardiac defibrillator)
Lab values
- Chronic kidney disease (estimated creatinine clearance \< 60 milliliters per minute (ml/min)
Other
- Already taking Allopurinol
- Magnetic Resonance Imaging Exclusion
- Claustrophobia
- Metal clips and/devices or other item that specifically prohibit safe cardiovascular magnetic resonance imaging (CMR)
Who the study is looking for
- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Veteran
- African American
- Resistant hypertension diagnosis (defined as blood pressure greater than 140/90 millimeters of mercury (mmHg) at 2 clinic visits despite the use of 3 antihypertensive medications at pharmacologically effective doses)
- Locale - Birmingham, AL and surrounding areas
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Birmingham VA Medical Center, Birmingham, AL Coordinator of this site? Confirm its status | Birmingham | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.